Llwytho...
The biology behind PI3K inhibition in chronic lymphocytic leukaemia
Phosphoinositide 3′-kinase (PI3K) is a key component of both chronic active and tonic B-cell receptor-signalling pathways. As such, PI3K inhibitors have emerged as promising therapeutic agents for diverse lymphoid malignancies, particularly chronic lymphocytic leukaemia. Multiple in vitro experiment...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ther Adv Hematol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4298491/ https://ncbi.nlm.nih.gov/pubmed/25642313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620714561581 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|